The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?

Research output: Contribution to journal › Review › Research › peer-review

Standard

The disease modifying osteoarthritis drug (DMOAD) : Is it in the horizon? / Qvist, Per; Bay-Jensen, Anne-Christine; Christiansen, Claus; Dam, Erik B; Pastoureau, Philippe; Karsdal, Morten A.

In: Pharmacological Research, Vol. 58, No. 1, 07.2008, p. 1-7.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Qvist, P, Bay-Jensen, A-C, Christiansen, C, Dam, EB, Pastoureau, P & Karsdal, MA 2008, 'The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?', Pharmacological Research, vol. 58, no. 1, pp. 1-7. https://doi.org/10.1016/j.phrs.2008.06.001

APA

Qvist, P., Bay-Jensen, A-C., Christiansen, C., Dam, E. B., Pastoureau, P., & Karsdal, M. A. (2008). The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? Pharmacological Research, 58(1), 1-7. https://doi.org/10.1016/j.phrs.2008.06.001

Vancouver

Qvist P, Bay-Jensen A-C, Christiansen C, Dam EB, Pastoureau P, Karsdal MA. The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? Pharmacological Research. 2008 Jul;58(1):1-7. https://doi.org/10.1016/j.phrs.2008.06.001

Author

Qvist, Per ; Bay-Jensen, Anne-Christine ; Christiansen, Claus ; Dam, Erik B ; Pastoureau, Philippe ; Karsdal, Morten A. / The disease modifying osteoarthritis drug (DMOAD) : Is it in the horizon?. In: Pharmacological Research. 2008 ; Vol. 58, No. 1. pp. 1-7.

Bibtex

@article{62b01ed1d1f249a5aa5c79d035dfec9c,
title = "The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?",
abstract = "Till date, the pharmaceutical industry has failed to bring effective and safe disease modifying osteoarthritic drugs (DMOADs) to the millions of patients suffering from this serious and deliberating disease. We provide a review of recent data reported on the investigation of DMOADs in clinical trials, including compounds inhibiting matrix-metalloproteinases (MMPs), bisphosphonates, cytokine blockers, calcitonin, inhibitors of inducible nitric oxide synthase (iNOS), doxycycline, glucosamine, and diacereine. We discuss the challenges associated with the drug development process in general and with DMOADs in particular, and we advance the need for a new development paradigm for DMOADs. Two central elements in this paradigm are a stronger focus on the biology of the joint and the application of new and more sensitive biomarkers allowing redesign of clinical trials in osteoarthritis.",
keywords = "Anthraquinones, Antirheumatic Agents, Calcitonin, Cytokines, Diphosphonates, Doxycycline, Glucosamine, Humans, Matrix Metalloproteinase Inhibitors, Nitric Oxide Synthase Type II, Osteoarthritis, Journal Article, Review",
author = "Per Qvist and Anne-Christine Bay-Jensen and Claus Christiansen and Dam, {Erik B} and Philippe Pastoureau and Karsdal, {Morten A}",
year = "2008",
month = jul,
doi = "10.1016/j.phrs.2008.06.001",
language = "English",
volume = "58",
pages = "1--7",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "1",

}

RIS

TY - JOUR

T1 - The disease modifying osteoarthritis drug (DMOAD)

T2 - Is it in the horizon?

AU - Qvist, Per

AU - Bay-Jensen, Anne-Christine

AU - Christiansen, Claus

AU - Dam, Erik B

AU - Pastoureau, Philippe

AU - Karsdal, Morten A

PY - 2008/7

Y1 - 2008/7

N2 - Till date, the pharmaceutical industry has failed to bring effective and safe disease modifying osteoarthritic drugs (DMOADs) to the millions of patients suffering from this serious and deliberating disease. We provide a review of recent data reported on the investigation of DMOADs in clinical trials, including compounds inhibiting matrix-metalloproteinases (MMPs), bisphosphonates, cytokine blockers, calcitonin, inhibitors of inducible nitric oxide synthase (iNOS), doxycycline, glucosamine, and diacereine. We discuss the challenges associated with the drug development process in general and with DMOADs in particular, and we advance the need for a new development paradigm for DMOADs. Two central elements in this paradigm are a stronger focus on the biology of the joint and the application of new and more sensitive biomarkers allowing redesign of clinical trials in osteoarthritis.

AB - Till date, the pharmaceutical industry has failed to bring effective and safe disease modifying osteoarthritic drugs (DMOADs) to the millions of patients suffering from this serious and deliberating disease. We provide a review of recent data reported on the investigation of DMOADs in clinical trials, including compounds inhibiting matrix-metalloproteinases (MMPs), bisphosphonates, cytokine blockers, calcitonin, inhibitors of inducible nitric oxide synthase (iNOS), doxycycline, glucosamine, and diacereine. We discuss the challenges associated with the drug development process in general and with DMOADs in particular, and we advance the need for a new development paradigm for DMOADs. Two central elements in this paradigm are a stronger focus on the biology of the joint and the application of new and more sensitive biomarkers allowing redesign of clinical trials in osteoarthritis.

KW - Anthraquinones

KW - Antirheumatic Agents

KW - Calcitonin

KW - Cytokines

KW - Diphosphonates

KW - Doxycycline

KW - Glucosamine

KW - Humans

KW - Matrix Metalloproteinase Inhibitors

KW - Nitric Oxide Synthase Type II

KW - Osteoarthritis

KW - Journal Article

KW - Review

U2 - 10.1016/j.phrs.2008.06.001

DO - 10.1016/j.phrs.2008.06.001

M3 - Review

C2 - 18590824

VL - 58

SP - 1

EP - 7

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 1

ER -

ID: 187554998